Equipped with pioneering infrastructure, purpose-built facilities, and advanced analytical platforms, Cadila CRO offers end-to-end research solutions, from protocol development and site management to bioanalytical testing and statistical analysis to study report delivery.

Established in 2003 and fully operational by 2005, Cadila CRO (DCGI-approved) is a reputable Clinical Research Organisation dedicated to advancing drug development through high-quality, ethical, and compliant research services. With more than twenty years of experience, we focus on Bioavailability/Bioequivalence (BA/BE) studies, Phase I-IV clinical trials, and pre-clinical research. We support pharmaceutical and biotech companies worldwide in their efforts to introduce safe and effective therapies to the market.
At the core of our operations is a commitment to scientific excellence, regulatory integrity, and patient safety. Our diverse team of experienced professionals collaborate to deliver reliable, timely results that align with global regulatory standards.
We partner with global sponsors to deliver personalised clinical development support backed by strong quality systems and a proactive, end-to-end approach across BA/BE, Phase-I, clinical trials, and pre-clinical studies.

To be a leader in advancing medical science by delivering innovative, ethical, and reliable pre-clinical and clinical research solutions.

To conduct ethical and transparent pre-clinical and clinical studies that bring safe and effective treatments to market while upholding the highest standards of care and integrity.


With extensive experience in successfully conducting Bioavailability and Bioequivalence (BA/BE) studies, our CRO remains a leader in clinical research excellence. We specialise in providing high-quality, compliant, and timely services that adhere to the strict standards of global regulatory agencies.
We offer end-to-end support for BA/BE studies across a wide range of therapeutic areas and dosage forms, from immediate- and modified-release formulations to complex generics.

We specialise in delivering end-to-end clinical trial services designed to support sponsors across every phase of drug development. With a commitment to scientific integrity, regulatory compliance, and operational excellence, our multidisciplinary team ensures the execution of clinical trials, from planning through submission.














The state-of-the-art OECD GLP-certified Pre-Clinical facility is spread over 5600 sq. ft. of laboratory space, in the sprawling, beautiful campus of Cadila. The animal house is designed in accordance with GLP & CPCSEA requirements.
The salient features of the animal house are: a double-corridor facility to ensure unidirectional flow of material, 100% exhaust in the breeding facility (no recirculation of air), and automated illumination, with 12 hours of lighting in a 24-hour cycle. The movement of material within the facility strictly follows the unidirectional flow.
Human Assets
Area of Expertise
Regulatory and Other Approvals


Contact Us
Our Story
Businesses
Therapies
Corporate Identification No : U24231GJ1991PLC015132
©2026 Cadila Pharmaceuticals. All rights reserved